Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO–(BUSINESS WIRE)–
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
- Citi’s 18th Annual BioPharma Conference
Date: Wednesday, September 6, 2023
Location: Boston, MA
Format: 1×1 Meetings
- Morgan Stanley 21st Annual Global Healthcare Conference
Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time
Location: New York, NY
Format: Fireside Chat and 1×1 Meetings
- TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time
Location: Virtual
Format: Fireside Chat
- Cantor Fitzgerald Global Healthcare Conference
Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time
Location: New York, NY
Format: Fireside Chat and 1×1 Meetings
Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
[email protected]
Investor Contact:
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
[email protected]
KEYWORDS: United States North America Massachusetts California New York
INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Neurology
MEDIA:
| Logo |
 |